PharmaLundensis（PHAL）株式概要PharmaLundensis AB operates as a pharmaceutical company. 詳細PHAL ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長0/6過去の実績0/6財務の健全性1/6配当金0/6リスク分析意味のある時価総額がありません ( SEK15M )収益が 100 万ドル未満 ( SEK0 )株式の流動性は非常に低い 過去1年間で株主の希薄化が進んだ +1 さらなるリスクすべてのリスクチェックを見るPHAL Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueSEK Current PriceSEK 0.36該当なし内在価値ディスカウントEst. Revenue$PastFuture-12m8k2016201920222025202620282031Revenue SEK 1.0Earnings SEK 0.2AdvancedSet Fair ValueView all narrativesPharmaLundensis AB 競合他社AptahemSymbol: NGM:APTAMarket cap: SEK 13.6mBiosergenSymbol: OM:BIOSGNMarket cap: SEK 10.9mProstatype GenomicsSymbol: OM:PROGENMarket cap: SEK 26.6mChosa OncologySymbol: NGM:CHOSAMarket cap: SEK 34.4m価格と性能株価の高値、安値、推移の概要PharmaLundensis過去の株価現在の株価SEK 0.3652週高値SEK 1.5152週安値SEK 0.16ベータ-0.311ヶ月の変化0%3ヶ月変化1.69%1年変化-44.62%3年間の変化-63.64%5年間の変化-90.58%IPOからの変化-90.77%最新ニュースお知らせ • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026お知らせ • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offeringお知らせ • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026お知らせ • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025お知らせ • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025お知らせ • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering最新情報をもっと見るRecent updatesお知らせ • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026お知らせ • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offeringお知らせ • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026お知らせ • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025お知らせ • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025お知らせ • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offeringお知らせ • Apr 02PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025お知らせ • Feb 06PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,439,654 Price\Range: SEK 1 Transaction Features: Rights Offeringお知らせ • Jan 22PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025お知らせ • Oct 23PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024お知らせ • Jul 17PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024お知らせ • Apr 17PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024お知らせ • Jan 17PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024お知らせ • Sep 22PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023Recent Insider Transactions • Sep 07Founder recently bought kr135k worth of stockOn the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares.お知らせ • Jul 21PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023Recent Insider Transactions • Jul 04Founder recently bought kr85k worth of stockOn the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares.New Risk • Jun 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).Recent Insider Transactions • Mar 16Founder recently bought kr96k worth of stockOn the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares.お知らせ • Jan 18PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Oct 19PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.お知らせ • Apr 20PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022Is New 90 Day High Low • Jan 29New 90-day low: kr0.86The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.Is New 90 Day High Low • Dec 01New 90-day low: kr0.94The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.Is New 90 Day High Low • Oct 24New 90-day low: kr1.01The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.Is New 90 Day High Low • Sep 23New 90-day low: kr1.02The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.お知らせ • Jul 26PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020株主還元PHALSE BiotechsSE 市場7D0%3.2%-0.6%1Y-44.6%28.0%11.4%株主還元を見る業界別リターン: PHAL過去 1 年間で28 % の収益を上げたSwedish Biotechs業界を下回りました。リターン対市場: PHALは、過去 1 年間で11.4 % のリターンを上げたSwedish市場を下回りました。価格変動Is PHAL's price volatile compared to industry and market?PHAL volatilityPHAL Average Weekly Movementn/aBiotechs Industry Average Movement9.8%Market Average Movement6.1%10% most volatile stocks in SE Market13.4%10% least volatile stocks in SE Market3.4%安定した株価: PHAL 、 Swedish市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: 過去 1 年間のPHALのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20061Staffan Skogvallwww.pharmalundensis.seもっと見るPharmaLundensis AB 基礎のまとめPharmaLundensis の収益と売上を時価総額と比較するとどうか。PHAL 基礎統計学時価総額SEK 15.28m収益（TTM）-SEK 4.40m売上高(TTM)n/a0.0xP/Sレシオ-3.5xPER（株価収益率PHAL は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計PHAL 損益計算書（TTM）収益SEK 0売上原価SEK 0売上総利益SEK 0その他の費用SEK 4.40m収益-SEK 4.40m直近の収益報告Dec 31, 2023次回決算日May 16, 2024一株当たり利益（EPS）-0.10グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率163.1%PHAL の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/29 11:20終値2024/01/31 00:00収益2023/12/31年間収益2023/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋PharmaLundensis AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026
お知らせ • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering
お知らせ • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026
お知らせ • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025
お知らせ • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025
お知らせ • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering
お知らせ • Apr 22PharmaLundensis AB to Report Q1, 2026 Results on May 21, 2026PharmaLundensis AB announced that they will report Q1, 2026 results on May 21, 2026
お知らせ • Jan 23PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 19.997256 million. Security Name: Shares Security Type: Common Stock Securities Offered: 39,994,512 Price\Range: SEK 0.5 Transaction Features: Rights Offering
お知らせ • Jan 21PharmaLundensis AB to Report Fiscal Year 2025 Results on Feb 19, 2026PharmaLundensis AB announced that they will report fiscal year 2025 results on Feb 19, 2026
お知らせ • Oct 22PharmaLundensis AB to Report Q3, 2025 Results on Nov 20, 2025PharmaLundensis AB announced that they will report Q3, 2025 results on Nov 20, 2025
お知らせ • Jul 23PharmaLundensis AB to Report Q2, 2025 Results on Aug 21, 2025PharmaLundensis AB announced that they will report Q2, 2025 results on Aug 21, 2025
お知らせ • Jun 10PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 20.09248 million. Security Name: Shares Security Type: Common Stock Securities Offered: 40,184,959 Price\Range: SEK 0.5 Transaction Features: Rights Offering
お知らせ • Apr 02PharmaLundensis AB to Report Q1, 2025 Results on May 01, 2025PharmaLundensis AB announced that they will report Q1, 2025 results on May 01, 2025
お知らせ • Feb 06PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million.PharmaLundensis AB has filed a Follow-on Equity Offering in the amount of SEK 14.439654 million. Security Name: Shares Security Type: Common Stock Securities Offered: 14,439,654 Price\Range: SEK 1 Transaction Features: Rights Offering
お知らせ • Jan 22PharmaLundensis AB to Report Fiscal Year 2024 Results on Feb 20, 2025PharmaLundensis AB announced that they will report fiscal year 2024 results on Feb 20, 2025
お知らせ • Oct 23PharmaLundensis AB to Report Nine Months, 2024 Results on Nov 21, 2024PharmaLundensis AB announced that they will report nine months, 2024 results on Nov 21, 2024
お知らせ • Jul 17PharmaLundensis AB to Report Q2, 2024 Results on Aug 15, 2024PharmaLundensis AB announced that they will report Q2, 2024 results on Aug 15, 2024
お知らせ • Apr 17PharmaLundensis AB to Report Q1, 2024 Results on May 16, 2024PharmaLundensis AB announced that they will report Q1, 2024 results on May 16, 2024
お知らせ • Jan 17PharmaLundensis AB to Report Fiscal Year 2023 Results on Feb 15, 2024PharmaLundensis AB announced that they will report fiscal year 2023 results on Feb 15, 2024
お知らせ • Sep 22PharmaLundensis AB to Report Nine Months, 2023 Results on Oct 20, 2023PharmaLundensis AB announced that they will report nine months, 2023 results on Oct 20, 2023
Recent Insider Transactions • Sep 07Founder recently bought kr135k worth of stockOn the 5th of September, Staffan Skogvall bought around 225k shares on-market at roughly kr0.60 per share. This transaction amounted to 1.1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr471k worth in shares.
お知らせ • Jul 21PharmaLundensis AB to Report Q2, 2023 Results on Aug 17, 2023PharmaLundensis AB announced that they will report Q2, 2023 results on Aug 17, 2023
Recent Insider Transactions • Jul 04Founder recently bought kr85k worth of stockOn the 30th of June, Staffan Skogvall bought around 274k shares on-market at roughly kr0.31 per share. This transaction amounted to 1.3% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr330k worth in shares.
New Risk • Jun 17New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 22% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr2.3m free cash flow). Share price has been highly volatile over the past 3 months (19% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (kr19.5m market cap, or US$1.83m). Minor Risk Shareholders have been diluted in the past year (22% increase in shares outstanding).
Recent Insider Transactions • Mar 16Founder recently bought kr96k worth of stockOn the 13th of March, Staffan Skogvall bought around 188k shares on-market at roughly kr0.51 per share. This transaction amounted to less than 1% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Staffan has been a buyer over the last 12 months, purchasing a net total of kr283k worth in shares.
お知らせ • Jan 18PharmaLundensis AB to Report Fiscal Year 2022 Results on Feb 16, 2023PharmaLundensis AB announced that they will report fiscal year 2022 results on Feb 16, 2023
Board Change • Nov 16No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Oct 19PharmaLundensis AB to Report Q3, 2022 Results on Nov 17, 2022PharmaLundensis AB announced that they will report Q3, 2022 results on Nov 17, 2022
Board Change • Apr 27No independent directorsThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 4 new directors. No experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Founder, CEO & Director Staffan Skogvall is the most experienced director on the board, commencing their role in 2006. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of experienced directors.
お知らせ • Apr 20PharmaLundensis AB to Report Q1, 2022 Results on May 19, 2022PharmaLundensis AB announced that they will report Q1, 2022 results on May 19, 2022
Is New 90 Day High Low • Jan 29New 90-day low: kr0.86The company is down 17% from its price of kr1.04 on 29 October 2020. The Swedish market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 4.0% over the same period.
Is New 90 Day High Low • Dec 01New 90-day low: kr0.94The company is down 19% from its price of kr1.16 on 01 September 2020. The Swedish market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 5.0% over the same period.
Is New 90 Day High Low • Oct 24New 90-day low: kr1.01The company is down 8.0% from its price of kr1.10 on 23 July 2020. The Swedish market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is down 3.0% over the same period.
Is New 90 Day High Low • Sep 23New 90-day low: kr1.02The company is down 15% from its price of kr1.20 on 25 June 2020. The Swedish market is up 12% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 16% over the same period.
お知らせ • Jul 26PharmaLundensis AB to Report Q2, 2020 Results on Aug 20, 2020PharmaLundensis AB announced that they will report Q2, 2020 results on Aug 20, 2020
